QUOTED. 14 May 2020. Stephen Hahn.
The US Food and Drug Administration has paused surveillance inspections due to the COVID-19 pandemic, but that doesn’t mean compliance doesn’t matter. Here’s what FDA Commissioner Stephen Hahn had to say about the issue.
“Safety and quality must be part of the daily routine at any regulated facility for their products to be high quality and reliably suitable for the US consumer. …The FDA’s regulatory oversight of crucial industry sectors is vital to the long-term health of America, but product safety and quality are ultimately the establishment’s responsibility.” – Stephen Hahn, commissioner, US FDA
Click here for a free trial of Medtech Insight